S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
NASDAQ:RAIN

Rain Oncology (RAIN) Price Target & Analyst Ratings

$1.03
-0.07 (-6.30%)
(As of 02:03 PM ET)
Compare
Today's Range
$0.94
▼
$1.14
50-Day Range
$1.10
▼
$9.93
52-Week Range
$0.94
▼
$14.48
Volume
4.52 million shs
Average Volume
786,135 shs
Market Capitalization
$37.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Rain Oncology Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 13 Analyst Ratings

Consensus Analyst Price Target

$17.00
1,549.36% Upside
High Prediction$24.00
Average Prediction$17.00
Low Prediction$11.00
TypeCurrent
5/30/22 to 5/30/23		1 Month Ago
4/30/22 to 4/30/23		3 Months Ago
3/1/22 to 3/1/23		1 Year Ago
5/30/21 to 5/30/22
Consensus Rating
Hold
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
2 Buy rating(s)
Hold
8 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.00$16.44$17.50$17.25
Predicted Upside1,549.36% Upside120.09% Upside156.10% Upside63.00% Upside
Get Rain Oncology Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter.


RAIN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RAIN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Rain Oncology Stock vs. The Competition

TypeRain OncologyMedical CompaniesS&P 500
Consensus Rating Score
2.42
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside1,445.45% Upside1,325.55% Upside197.55% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/30/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
5/23/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Neutral
5/23/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
5/22/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
5/22/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Slutsky
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
5/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
5/22/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Neutral
5/22/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
3/21/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$11.00+41.57%
3/13/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$18.00 ➝ $17.00+89.10%
3/10/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$16.00+82.44%
1/31/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy$21.00+116.94%
6/23/2022Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$17.00+556.37%
(Data available from 5/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RAIN Price Target - Frequently Asked Questions

What is Rain Oncology's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 8 hold ratings and 5 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00. Learn more on RAIN's analyst rating history.

Do Wall Street analysts like Rain Oncology more than its competitors?

Analysts like Rain Oncology less than other Medical companies. The consensus rating for Rain Oncology is Hold while the average consensus rating for medical companies is Buy. Learn more on how RAIN compares to other companies.

Is Rain Oncology being downgraded by Wall Street analysts?

Over the previous 90 days, Rain Oncology's stock had 8 downgrades by analysts.

Does Rain Oncology's stock price have much upside?

According to analysts, Rain Oncology's stock has a predicted upside of 121.38% based on their 12-month price targets.

What analysts cover Rain Oncology?

Rain Oncology has been rated by Citigroup, EF Hutton Acquisition Co. I, Guggenheim, HC Wainwright, Lifesci Capital, Mizuho, Oppenheimer, Piper Sandler, Roth Mkm, SVB Leerink, and SVB Securities in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:RAIN) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -